Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
Date:10/1/2010

llular immunotherapy. It is designed to be an active cellular immunotherapy. Active cellular immunotherapy is designed to stimulate a T-cell response to cancer cells. An immune response is started by a specialized class of immune system cells called antigen-presenting cells (APCs). APCs take up antigens from their surroundings and process the antigens into fragments that are then displayed on the APC's surface. Once displayed, these antigens can be recognized by specific classes of immune cells called T lymphocytes (T-cells), which are activated as a result of their engagement with APCs and combat disease by seeking antigen-bearing cells directly. PROVENGE is designed to target the prostate cancer antigen prostatic acid phosphatase (PAP), an antigen that is expressed in more than 95 percent of all prostate cancers.

About Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factor
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Ala. , Aug. 27, 2015 /PRNewswire/ ... Outpatient Pharmacy Provider (IOPP™) is expanding its ... of a medication-focused transition of care program ... named "RxCare Management," provides hospitals with technology ... hospital performance measures that have been mandated ...
(Date:8/27/2015)... , Aug. 27, 2015  A mere one ... Booz Allen Hamilton . A new white ... development inefficiencies are impeding and disrupting manufacturers, success. ... Waste and Improve Value In Product Development Processes ... inaccessible data and how it affects the product development ...
(Date:8/27/2015)... NorthStar Anesthesia , one of the country,s ... selected by Mercy, based in Toledo, Ohio ... hospitals:  Mercy St. Vincent  Medical Center and Mercy St. ... St. Charles  Hospital in Oregon and ... "As we looked to create a more ...
Breaking Medicine Technology:Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2
... CYBX ), a global leader in epilepsy management, today ... Sciences Conference on Wednesday, September 21, 2011, in New York. ... will speak to the attendees of the conference 10:00 AM ... be accessed by clicking on the Investor Relations link on ...
... 7, 2011 Generex Biotechnology Corporation ( www.generex.com ... the Company,s President & Chief Executive Officer, and ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ) ... & Renshaw 13th Annual Healthcare Conference.  The presentation ...
Cached Medicine Technology:Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 3
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to ... a cutting-edge, noninvasive procedure to improve submental fat. The first and only Food ... without surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, making ... Insurance is sharing some tips to help your whole family travel safely and comfortably. ... with pets each year. Amica is sharing the following tips from the American Society ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... Analysis signed a partnership agreement for quality market research promotion on the ... by Black Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its ... grown to having twelve offices in three counties, LA, Orange and San Bernardino. ... California region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope ...
Breaking Medicine News(10 mins):Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
... patients with the help of seroquel is effective//, ... chronic severe disabling mental illness. Some of the ... heard, feelings of being persecuted, becoming withdrawn, and ... only one in five patients have a chance ...
... diabetes drug thiazolidinediones (TZDs) can cause //edema. ,Scientists from ... activates a receptor in kidney called peroxisome proliferator-activated receptor gamma ... kidney. The activation of the receptor serves to retain the ... are generally used to lower blood sugar levels and lipid ...
... increase the risk of the Alzheimer’s disease// if people ... to a research study that is presented in the ... held in US, periodontal conditions could affect the incidence ... the brain cells and slowly destroys them. The main ...
... friendship that can keep people have a long life//. ... of having friends do affect the health and emotional well ... get significantly increased. ,The researchers had surveyed about ... the phone for about ten years in the age group ...
... had licensed the use of strontium ranelate to be used ... prescribing the drug it is important to observe the changes ... British Medical Journal has said that the drug strontium ranelate ... that this effect can be used in advantage of the ...
... have shown that consumption of trans fatty acids ... disease. Trans fatty acids are the hydrogenated and ... baked goods and many processed foods. They are ... in the presence of metal catalysts and in ...
Cached Medicine News:
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... can operate in two additional modes. The ... creating a fully featured handheld pulse oximeter, ... used to upgrade existing equipment through the ... or software upgrades to improve the performance ...
... The stylish Avant® 9600s simple functionality, ... of memory makes it well-suited for ... proven digital pulse oximetry, the Avant ... rugged durability. The 9600 provides a ...
Medicine Products: